Nanotechnology Approaches for Enhanced CNS Drug Delivery in the Management of Schizophrenia

Overview

Journal Adv Pharm Bull

Date 2022 Aug 8

PMID 35935056

Authors

Rajalakshmi Rajendran

Krishnakumar Neelakandha Menon

Sreeja Chandrasekharan Nair

Affiliations

Soon will be listed here.

Abstract

Schizophrenia is a neuropsychiatric disorder mainly affecting the central nervous system (CNS), presented with auditory and visual hallucinations, delusion and withdrawal from society. Abnormal dopamine levels mainly characterise the disease; various theories of neurotransmitters explain the pathophysiology of the disease. The current therapeutic approach deals with the systemic administration of drugs other than the enteral route, altering the neurotransmitter levels within the brain and providing symptomatic relief. Fluid biomarkers help in the early detection of the disease, which would improve the therapeutic efficacy. However, the major challenge faced in CNS drug delivery is the blood-brain barrier (BBB). Nanotherapeutic approaches may overcome these limitations, which will improve safety, efficacy, and targeted drug delivery. This review article addresses the main challenges faced in CNS drug delivery and the significance of current therapeutic strategies and nanotherapeutic approaches for a better understanding and enhanced drug delivery to the brain, which improve the quality of life of schizophrenia patients.

Citing Articles

Applications of Nanoporous Gold in Therapy, Drug Delivery, and Diagnostics.

Sondhi P, Lingden D, Bhattarai J, Demchenko A, Stine K Metals (Basel). 2024; 13(1).

PMID: 39238564 PMC: 11376205. DOI: 10.3390/met13010078.

Association between voriconazole-induced visual hallucination and dopamine in an analysis of the food and drug administration (FDA) adverse event reporting system database.

Kato H, Shiraishi C, Hagihara M, Mikamo H, Iwamoto T Sci Rep. 2024; 14(1):12519.

PMID: 38822123 PMC: 11143338. DOI: 10.1038/s41598-024-63504-y.

References

Katare Y, Daya R, Sookram Gray C, Luckham R, Bhandari J, Chauhan A . Brain Targeting of a Water Insoluble Antipsychotic Drug Haloperidol via the Intranasal Route Using PAMAM Dendrimer. Mol Pharm. 2015; 12(9):3380-8. DOI: 10.1021/acs.molpharmaceut.5b00402. View

Comer A, Carrier M, Tremblay M, Cruz-Martin A . The Inflamed Brain in Schizophrenia: The Convergence of Genetic and Environmental Risk Factors That Lead to Uncontrolled Neuroinflammation. Front Cell Neurosci. 2020; 14:274. PMC: 7518314. DOI: 10.3389/fncel.2020.00274. View

Khan K, Akhtar N, Usman Minhas M . Poloxamer-407-Co-Poly (2-Acrylamido-2-Methylpropane Sulfonic Acid) Cross-linked Nanogels for Solubility Enhancement of Olanzapine: Synthesis, Characterization, and Toxicity Evaluation. AAPS PharmSciTech. 2020; 21(5):141. DOI: 10.1208/s12249-020-01694-0. View

Yanuck S . Microglial Phagocytosis of Neurons: Diminishing Neuronal Loss in Traumatic, Infectious, Inflammatory, and Autoimmune CNS Disorders. Front Psychiatry. 2019; 10:712. PMC: 6786049. DOI: 10.3389/fpsyt.2019.00712. View

Wolf R, Kubera K, Waddington J, Schmitgen M, Fritze S, Rashidi M . A neurodevelopmental signature of parkinsonism in schizophrenia. Schizophr Res. 2021; 231:54-60. DOI: 10.1016/j.schres.2021.03.004. View

Rautio J, Laine K, Gynther M, Savolainen J . Prodrug approaches for CNS delivery. AAPS J. 2008; 10(1):92-102. PMC: 2751454. DOI: 10.1208/s12248-008-9009-8. View

Kara I, Penner M . Impact of Antipsychotic Guidelines on Laboratory Monitoring in Children with Neurodevelopmental Disorders. J Child Adolesc Psychopharmacol. 2020; 31(1):79-83. PMC: 7891197. DOI: 10.1089/cap.2020.0096. View

Caporarello N, DAngeli F, Cambria M, Candido S, Giallongo C, Salmeri M . Pericytes in Microvessels: From "Mural" Function to Brain and Retina Regeneration. Int J Mol Sci. 2019; 20(24). PMC: 6940987. DOI: 10.3390/ijms20246351. View

Esen-Sehir D, Courtney M, Bittner R, Reif A, Freudenberg F . Establishing an effective dose for chronic intracerebroventricular administration of clozapine in mice. Acta Neuropsychiatr. 2019; 31(6):305-315. DOI: 10.1017/neu.2019.31. View

10.

Ayka A, Ozer Sehirli A . The Role of the SLC Transporters Protein in the Neurodegenerative Disorders. Clin Psychopharmacol Neurosci. 2020; 18(2):174-187. PMC: 7236796. DOI: 10.9758/cpn.2020.18.2.174. View

11.

Upadhyay P, Trivedi J, Pundarikakshudu K, Sheth N . Direct and enhanced delivery of nanoliposomes of anti schizophrenic agent to the brain through nasal route. Saudi Pharm J. 2017; 25(3):346-358. PMC: 5357100. DOI: 10.1016/j.jsps.2016.07.003. View

12.

Joseph E, Reddi S, Rinwa V, Balwani G, Saha R . Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects. Eur J Pharm Sci. 2017; 104:315-325. DOI: 10.1016/j.ejps.2017.03.050. View

13.

Dias M, Mapunda J, Vladymyrov M, Engelhardt B . Structure and Junctional Complexes of Endothelial, Epithelial and Glial Brain Barriers. Int J Mol Sci. 2019; 20(21). PMC: 6862204. DOI: 10.3390/ijms20215372. View

14.

Coulthard L, Woodruff T . Commentary: Beyond C4: Analysis of the complement gene pathway shows enrichment for IQ in patients with psychotic disorders and healthy controls. Front Immunol. 2019; 10:2853. PMC: 6904300. DOI: 10.3389/fimmu.2019.02853. View

15.

Corradetti G, Violanti S, Au A, Sarraf D . Wide field retinal imaging and the detection of drug associated retinal toxicity. Int J Retina Vitreous. 2020; 5(Suppl 1):26. PMC: 6907121. DOI: 10.1186/s40942-019-0172-0. View

16.

Gu C, Kim G, Kim W, Kim H, Lee S . Current status and applications of genome-scale metabolic models. Genome Biol. 2019; 20(1):121. PMC: 6567666. DOI: 10.1186/s13059-019-1730-3. View

17.

Macklin A, Khan S, Kislinger T . Recent advances in mass spectrometry based clinical proteomics: applications to cancer research. Clin Proteomics. 2020; 17:17. PMC: 7247207. DOI: 10.1186/s12014-020-09283-w. View

18.

Yang T, Xiao T, Sun Q, Wang K . The current agonists and positive allosteric modulators of 7 nAChR for CNS indications in clinical trials. Acta Pharm Sin B. 2017; 7(6):611-622. PMC: 5687317. DOI: 10.1016/j.apsb.2017.09.001. View

19.

Brisch R, Saniotis A, Wolf R, Bielau H, Bernstein H, Steiner J . The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry. 2014; 5:47. PMC: 4032934. DOI: 10.3389/fpsyt.2014.00047. View

20.

Goyal A, Singh R, Chauhan G, Rath G . Non-invasive systemic drug delivery through mucosal routes. Artif Cells Nanomed Biotechnol. 2018; 46(sup2):539-551. DOI: 10.1080/21691401.2018.1463230. View